Why is Moderna suing Pfizer and BioNTech over its COVID-19 vaccine despite recent pledge?

This Commentary article explores the applications of mRNA therapeutics in disease treatment and prevention. The commercial presence of microfluidics technologies has improved process development, and has helped to provide rapid development along with the existence of established formulation principles for vaccines.

We interview Vincent Dewar, Associate Director and Head of Immunoassay Analytical Research Development at GlaxoSmithKline, to learn more about the importance of immunoassays for vaccine development.

How can the use of human stem cell models of neurodegenerative disease advance drug discovery? Clare Jones, Chief Scientific Officer at Talisman Therapeutics, investigates.

Oncology is almost always oriented towards simultaneous treatment options. We explore why as well as the approach’s unique challenges.

We interview Martin Akerman, Chief Technology Officer and Co-Founder at Envisagenics to find out about machine learning for drug target discovery in RNA.

The 2021 report is in, but who made the cut?

Vyepti is the first intravenous medication approved for migraine treatment.

With influenza expected to make a return this winter, vaccine manufacturers may be facing more demand than usual.

Children between one and nine years old to be given polio jab to curb the spread of the virus throughout the city.

The present and the future, key insights into the cell and gene therapy manufacturing space

How worrying is the new ‘Langya’ virus spreading in China?